Lv1
38 积分 2026-06-22 加入
British Nuclear Medicine Society Spring Meeting 13th - 15th May 2024
2天前
已关闭
Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study)
2天前
已关闭
Imaging screening with [68Ga]-Ga-PSMA-11, [18F]F-FDG, and [18F]-FCholine PET/CT for [177Lu]-PSMA radioligand therapy eligibility in mCRPC
2天前
已完结
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
2天前
已完结
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
4天前
已完结
EANM’24 Abstract Book Congress Oct 19-23, 2024
4天前
已完结
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)
4天前
已完结
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
4天前
已完结
Prognostic Outcomes of [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in High-Volume and Low-Volume Metastatic Castration-Resistant Prostate Cancer
5天前
已完结
Prognostic Impact of Liver Metastases on [177Lu]Lu-PSMA Therapy Outcomes in Metastatic Castration-Resistant Prostate Cancer
5天前
已完结
皖公网安备34019202002308
